top of page
EpiGeneer 2.png

EpiGeneer is developing a first-in-class regenerative therapy for Multiple Sclerosis, targeting global epigenetic mechanisms controlling remyelination
 

Independent Expert Evaluation

  • EpiGeneer is currently undergoing independent scientific and business evaluation through the BioExpert Network.​

​​

  • If you are a qualified life science professional (e.g. PhD, MD, Professor, industry expert in biotech/pharma) and would like to contribute to the independent evaluation process, we would be grateful for your participation.

​​

👉  https://bioexpertnetwork.com/register/?referral=NjEzOQ==

bottom of page